top of page


Supernus and Indivior complete merger to create diversified CNS biopharmaceutical company
Supernus and Indivior have completed a merger of equals, creating a diversified central nervous system biopharmaceutical company with an 11-product portfolio spanning addiction treatment, psychiatry and neurology.

nuaxia
Nov 32 min read


Supernus and Indivior agree merger to create $2.2 billion CNS biopharmaceutical company
The all-stock transaction combines complementary central nervous system portfolios spanning neuroscience and addiction medicine, creating a larger commercial-stage company with a broader product portfolio and pipeline.

nuaxia
Aug 62 min read
bottom of page